Advertisement
Mayo Clinic Proceedings Home

Increasing the Dose of Varenicline in Patients Who Do Not Respond to the Standard Dose

      Abstract

      Varenicline is a partial agonist of α4β2 nicotinic acetylcholine receptors. It is effective at dosages of 2 mg/d for 12 weeks, but not for all smokers. It is possible that increasing the dose can increase the drug efficacy. We reviewed the clinical records of consecutive smokers who had been treated in 2 smoking cessation services with varenicline at doses of 3 mg/d. In all cases, the treatment program consisted of a combination of behavioral therapy and drug treatment. Varenicline was prescribed at a standard dosage for 8 weeks. After 8 weeks of treatment, the dose was increased to 3 mg/d if patients tolerated varenicline well and continued smoking or, in spite of not smoking, if they experienced severe withdrawal symptoms. The sample included 73 patients, of whom 52 continued to smoke at 8 weeks and 21 stopped smoking but reported severe withdrawal discomfort. Carbon monoxide-validated continuous abstinence rates from week 9 to week 24 were 40% and 48% in these 2 subgroups, respectively. The increase in dosage was associated with adverse events in 22 patients (30%). These were mostly mild and included nausea, vomiting, abnormal dreams, and insomnia. Only 2 patients discontinued treatment (both because of nausea and vomiting). Thus, we conclude that increasing the varenicline dose in smokers who do not respond to the standard dose after 8 weeks of treatment is associated with limited adverse events and high success rates.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Mayo Clinic Proceedings
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Reus V.I.
        • Obach R.S.
        • Coe J.W.
        • et al.
        Varenicline: new treatment with efficacy in smoking cessation.
        Drugs Today (Barc). 2007; 43: 65-75
        • Cahill K.
        • Stead L.F.
        • Lancaster T.
        Nicotine receptor partial agonists for smoking cessation.
        Cochrane Database Syst Rev. 2012; 4: CD006103
        • 2008 PHS Guideline Update Panel, Liaisons, and Staff
        Treating tobacco use and dependence: 2008 update U.S. Public Health Service Clinical Practice Guideline executive summary.
        Respir Care. 2008; 53: 1217-1222
        • Hajek P.
        • McRobbie H.J.
        • Myers K.E.
        • Stapleton J.
        • Dhanji A.R.
        Use of varenicline for 4 weeks before quitting smoking: decrease in ad lib smoking and increase in smoking cessation rates.
        Arch Intern Med. 2011; 171: 770-777